HK1209455A1 - Pluripotent germ layer origin antigen presenting cancer vaccine - Google Patents

Pluripotent germ layer origin antigen presenting cancer vaccine Download PDF

Info

Publication number
HK1209455A1
HK1209455A1 HK15110097.4A HK15110097A HK1209455A1 HK 1209455 A1 HK1209455 A1 HK 1209455A1 HK 15110097 A HK15110097 A HK 15110097A HK 1209455 A1 HK1209455 A1 HK 1209455A1
Authority
HK
Hong Kong
Prior art keywords
cells
cancer
cell
ifn
melanoma
Prior art date
Application number
HK15110097.4A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew CORNFORTH
Robert DILLMAN
Original Assignee
Caladrius Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caladrius Biosciences, Inc. filed Critical Caladrius Biosciences, Inc.
Publication of HK1209455A1 publication Critical patent/HK1209455A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15110097.4A 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine HK1209455A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594304P 2012-02-02 2012-02-02
US61/594304 2012-02-02
PCT/US2013/024123 WO2013116505A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Publications (1)

Publication Number Publication Date
HK1209455A1 true HK1209455A1 (en) 2016-04-01

Family

ID=48905824

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15110097.4A HK1209455A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine
HK15103009.6A HK1202432A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15103009.6A HK1202432A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Country Status (13)

Country Link
US (1) US20150064217A1 (enExample)
EP (1) EP2809775B1 (enExample)
JP (1) JP2015506698A (enExample)
KR (1) KR20140143361A (enExample)
CN (1) CN104540937A (enExample)
AU (1) AU2013215116A1 (enExample)
CA (1) CA2863653A1 (enExample)
GB (1) GB2512558A (enExample)
HK (2) HK1209455A1 (enExample)
IL (1) IL233928A0 (enExample)
NZ (1) NZ628292A (enExample)
SG (1) SG11201404543UA (enExample)
WO (2) WO2013116541A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
JP6423889B2 (ja) 2014-10-07 2018-11-14 サイトリミック株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3527216B1 (en) 2016-10-11 2024-02-14 NEC Corporation A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
CN110198717A (zh) * 2017-01-11 2019-09-03 国立研究开发法人国立癌症研究中心 免疫治疗药
EP3582793A4 (en) * 2017-02-17 2020-12-16 Aivita Biomedical, Inc. METHODS TO IMPROVE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS ANTI-CANCER IMMUNOTHERAPEUTICS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
EP2322603B1 (en) * 2001-09-06 2019-10-16 NorthWest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response
WO2006047515A2 (en) * 2004-10-25 2006-05-04 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
JP5281399B2 (ja) * 2005-07-29 2013-09-04 プロビデンス ヘルス システム 小胞（ｄｒｉｂｂｌｅ）中の不完全なリボソーム産物、および免疫応答を刺激するための使用方法
WO2008039974A2 (en) * 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Also Published As

Publication number Publication date
IL233928A0 (en) 2014-09-30
WO2013116505A1 (en) 2013-08-08
GB201414403D0 (en) 2014-10-01
CN104540937A (zh) 2015-04-22
SG11201404543UA (en) 2014-08-28
US20150064217A1 (en) 2015-03-05
NZ628292A (en) 2016-09-30
EP2809775A4 (en) 2015-07-01
HK1202432A1 (en) 2015-10-02
GB2512558A (en) 2014-10-01
KR20140143361A (ko) 2014-12-16
CA2863653A1 (en) 2013-08-08
EP2809775A1 (en) 2014-12-10
EP2809775B1 (en) 2018-06-13
WO2013116541A1 (en) 2013-08-08
AU2013215116A1 (en) 2014-08-21
JP2015506698A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
Palucka et al. Recent developments in cancer vaccines
Navabi et al. A clinical grade poly I: C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro
US9555058B2 (en) Antigen presenting cancer vaccine
Kumar et al. Immune modulation by dendritic-cell-based cancer vaccines
EP2809775B1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
AU2023208190A1 (en) Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
Flores et al. Dendritic Cells Loaded with Heat Shock‐Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell‐Dependent Antitumor Immune Responses In Vitro
Bot et al. Cancer vaccines
HK1230080A1 (en) Antigen presenting cancer vaccine with gamma interferon
Stepanek et al. Effects of 5-azacytidine and trichostatin A on dendritic cell maturation
NZ623917B2 (en) Antigen presenting cancer vaccine
HK1258885B (en) Methods relating to activated dendritic cell compositions for subjects with advanced cancers